+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are conducting a large prospective, observational cohort study to evaluate the clinical impact of new Monoclonal Antibodies MAB in patients with B-cell Non-Hodgkin Lymphoma NHL treated in Italian clinical practice. The study focuses on collecting information about the use, feasibility, effectiveness, and both short- and long-term side effects of novel MABs that have been approved by the European Medicines Agency since 2020 and prescribed according to authorized indications in Italy. Participants will be divided into groups based on treatment indication, antibody type, and lymphoma subtype to allow detailed analysis. The study observes patients with B-cell NHL who have received at least one dose of a novel MAB either alone or in combination, as authorized for use in Italy. Both patients receiving first-line treatment and those with relapsed or refractory disease are included. Various cohorts and sub-cohorts will be analyzed to understand outcomes by indication, antibody type, and histological subtype, providing a comprehensive overview of these treatments in real-life settings. Participants will be followed for at least five years to assess outcomes such as overall response rate, complete response rate, progression-free survival, overall survival, event-free survival, time to next treatment, non-relapse mortality, duration of response, and the incidence of early and late adverse events. Clinical data collection will include treatment details, safety monitoring, and long-term follow-up to evaluate both effectiveness and toxicity. The study spans several years, allowing researchers to capture extensive real-world evidence on novel MAB use in B-cell NHL.

Age: 18Years +All Genders
61 locations
E

Actively Recruiting

This research aims to enhance self-management skills for adults with Type 2 Diabetes Mellitus T2DM living in the Marche region of Italy. It evaluates a mobile health m-health solution personalized by diabetologists and integrated with electronic patient records, comparing its use to usual diabetes care. The main goal is to measure changes in glycated haemoglobin HbA1c levels over a 12-month period to assess the effectiveness of this digital support. Participants will be randomly assigned to either a treated group using the m-health solution or a control group receiving regular care. The m-health system includes mobile apps for tracking health data such as blood sugar, physical activity, and diet, sending alerts and motivational messages, allowing communication with healthcare professionals, and providing access to educational materials. Healthcare providers will monitor patient data through an integrated electronic platform. The treatment lasts 12 months with evaluations at baseline, 4, 8, and 12 months. During the study, participants will engage in clinical assessments and complete validated questionnaires covering disease severity, medication adherence, lifestyle habits, self-efficacy, and quality of life. Data will be collected from self-reports, clinical visits, and the m-health app. Researchers will also explore patients experience and satisfaction with the m-health solution and assess its cost-effectiveness. No extra visits or lab tests beyond routine care are required.

Age: 18Years +All GendersPhase Not Applicable
11 locations
E

Actively Recruiting

The study focuses on patients with various conditions related to plasma cells, including Monoclonal Gammopathy of Undetermined Significance MGUS, smoldering Multiple Myeloma SMM, Multiple Myeloma MM, and Plasma Cell Leukemia PCL. It is an observational, non-interventional, multicenter research project aimed at collecting, storing, and analyzing biological samples from these patients. The purpose is to create an international infrastructure for gathering consistent clinical data and biological samples at different stages of disease and treatment. Participants provide biological samples such as bone marrow aspirate, bone marrow biopsy, extramedullary disease EMD biopsy, peripheral blood, and serum at multiple timepoints. These include baseline, pre-maintenance or after one year of therapy depending on transplant eligibility, during maintenance therapy if part of standard care, and at first or later progression of disease. The study collects and stores these samples over a long period to support future research. Participants will undergo sample collections at scheduled times during their disease course and treatment phases. Researchers will monitor and analyze the stored biological samples and clinical data to support a biobank lasting up to 30 years. The study does not involve any experimental treatments but focuses on gathering data and samples to better understand the conditions. Participation requires written informed consent and compliance with the protocols follow-up schedule.

Age: 18Years +All Genders
41 locations
S

Actively Recruiting

Researchers are investigating the relationship between MYC gene changes, lymphoma genetic mutations, and the immune environment in adults with Diffuse Large B-cell Lymphoma DLBCL or High-Grade B-cell Lymphoma HGBCL. These lymphomas are diverse diseases making up over a third of adult lymphomas, with survival rates of around 60-70% over five years. The study aims to better understand these genetic factors and their impact on disease outcomes to improve treatment approaches. This observational study includes patients diagnosed with DLBCL or HGBCL who have MYC gene rearrangements or increased MYC gene copies. Participants have received standard first-line chemotherapy treatments such as R-CHOP or intensified regimens. The study collects data retrospectively and prospectively to explore genetic markers, immune cell patterns, and clinical outcomes related to these MYC changes and other genetic alterations. Participants provide tissue samples and clinical information, which researchers analyze for genetic and histological features. The study evaluates how these factors relate to patient responses and survival over up to 36 months. Researchers also review treatment types, risk of disease recurrence, and the effectiveness of preventive therapies. The study spans from diagnosis after January 2019 through long-term follow-up, helping to identify potential prognostic and predictive markers in lymphoma.

Age: 18Years - 79YearsAll Genders
20 locations
P

Actively Recruiting

Researchers are evaluating the effect of adding gemtuzumab ozogamicin to standard chemotherapy for adults aged 18 to 60 with newly diagnosed favorable or intermediate-risk acute myeloid leukemia AML. This phase 3 study aims to reduce minimal residual disease MRD levels before transplantation and assess whether MRD-driven post-remission therapy can improve anti-leukemic outcomes. The study excludes patients with certain genetic markers or prior treatments to focus on a specific AML subgroup. Participants receive induction treatment with gemtuzumab, daunorubicin, and cytosine arabinoside, followed by consolidation therapy with adjusted doses of these drugs. After consolidation, patients undergo either autologous or allogeneic stem cell transplantation based on their MRD level. This MRD-guided approach helps tailor the intensity of post-remission therapy. Throughout the study, participants undergo MRD assessments to measure treatment activity, with the primary outcome being MRD negativity two months after starting therapy. Researchers also monitor kidney and liver function, heart health, and overall compliance with study procedures. The study involves regular clinical observations and assessments to evaluate the effectiveness of the combined treatment and its impact on MRD levels over time.

Age: 18Years - 60YearsAll GendersPhase 3
48 locations
R

Actively Recruiting

Researchers are investigating a new treatment approach for adults with newly diagnosed acute myeloid leukemia AML who have specific genetic mutations NPM1 or KMT2A and are not eligible for intensive chemotherapy. Although current treatment combining azacitidine and venetoclax has improved outcomes, it is not curative and relapses occur. This Phase 3 study aims to determine if adding the investigational drug revumenib, which blocks a molecule called menin involved in leukemia cell production, can improve patient prognosis. Participants will be randomly assigned to receive either revumenib or a placebo, both in combination with azacitidine and venetoclax. Treatment cycles last 28 days and continue until the disease progresses, unacceptable side effects develop, death occurs, or other protocol criteria require stopping treatment. After the last patient joins the study, there will be a 4-year follow-up period to monitor survival and conduct additional visits. During the study, participants will undergo regular assessments to evaluate overall survival, remission rates, event-free survival, quality of life, and molecular responses using bone marrow and blood tests. Safety and treatment effects will be closely monitored throughout the treatment and follow-up periods. Participants must be adults with confirmed mutations and meet specific health criteria to join this trial.

Age: 18Years +All GendersPhase 3
201 locations